AbbVie
Develops immunology, neuroscience, oncology, and aesthetics products led by Skyrizi and Rinvoq.
$255.80
After-hours close+0.33 (+0.13%)
At close$255.47(−1.04%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 114.51%Insiders 0.08%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 1.77B · Float 1.76B · 99.8% free float
Institutions13F, as of Jun 30, 2026
4,324 holders · 2.02B shares · 294 new positions · 2,196 increased · 1,548 reduced · 181 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 149.49M | 8.46% | −1.21M | Aug 7, 2026 |
| Vanguard Capital Management LLC | 115.40M | 6.53% | +515.8K | Aug 13, 2026 |
| State Street Corp | 82.60M | 4.67% | +1.38M | Aug 7, 2026 |
| Vanguard Portfolio Management LLC | 48.48M | 2.74% | −1.05M | Aug 13, 2026 |
| JPMorgan Chase & Co | 47.86M | 2.71% | −8.88M | Aug 12, 2026 |
| Geode Capital Management, LLC | 47.00M | 2.66% | +260.9K | Aug 12, 2026 |
| Morgan Stanley | 38.90M | 2.20% | +884.2K | Aug 13, 2026 |
| Capital Research Global Investors | 30.10M | 1.70% | −1.15M | Aug 12, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Vanguard Capital Management | 7.51% | 132.92M | 13G | Apr 29, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Richard A. Gonzalez | director | 386.5K | 0.02% | Apr 2, 2025 |
| Azita Saleki-Gerhardt | officer: EVP, CHIEF OPERATIONS OFFICER | 197.8K | 0.01% | Mar 3, 2026 |
| Robert A. Michael | director, officer: CHAIRMAN OF THE BOARD AND CEO | 178.7K | 0.01% | Mar 3, 2026 |
| Thomas C. Freyman | director | 131.9K | 0.01% | May 12, 2026 |
| Jeffrey Ryan Stewart | officer: EVP, CHIEF COMMERCIAL OFFICER | 83.2K | 0.00% | Mar 3, 2026 |
| Nicholas Donoghoe | officer: EVP, CHIEF BUS/STRAT OFFICER | 74.4K | 0.00% | Aug 18, 2026 |
| Roopal Thakkar | officer: EVP, R&D and CSO | 52.4K | 0.00% | Mar 3, 2026 |
| Glenn F. Tilton | director | 51.6K | 0.00% | May 13, 2025 |
| Edward J. Rapp | director | 46.0K | 0.00% | May 12, 2026 |
| Roxanne S. Austin | director | 39.6K | 0.00% | May 12, 2026 |
13 people have not refiled in the last 18 months (1.15M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 14, 2026 | Nicholas Donoghoeofficer: EVP, CHIEF BUS/STRAT OFFICER | Sale | 32,710 | $250.00 | 74,430 |
| Mar 4, 2026 | David Ryan Purdueofficer: SVP, Controller | Sale | 5,230 | $233.56 | 2,654 |
| Mar 2, 2026 | Perry C. Siatisofficer: EVP, GC AND SECRETARY | Sale · 3 lots | 18,668 | $234.39 | 4,619 |
| Feb 25, 2026 | Perry C. Siatisofficer: EVP, GC AND SECRETARY | Sale | 22,381 | $230.00 | 38,137 |
CongressHouse and Senate disclosures
| Member | Type | Amount | Owner | Traded | Disclosed |
|---|---|---|---|---|---|
| Rep. Ro Khanna · CA17 | Purchase | $15,001 – $50,000 | May 1, 2026 | Jun 11, 2026 ↗ | |
| Rep. Josh Gottheimer · NJ05 | Sale | $1,001 – $15,000 | Joint | May 5, 2026 | Jun 4, 2026 ↗ |